Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
2021-03-03 Sale |
2021-03-05 5:44 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
3,475 | $150.78 | $523,961 | 59,055 (Direct) |
View |
2021-02-22 Sale |
2021-02-24 4:16 pm |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
6,500 | $175.5 | $1,140,750 | 27,597 (Direct) |
View |
2021-01-15 Sale |
2021-01-19 5:00 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
63,814 | $172.48 | $11,006,647 | 59,660 (Direct) |
View |
2020-12-21 Sale |
2020-12-22 6:39 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
2,484 | $156.71 | $389,268 | 46,742 (Direct) |
View |
2020-12-18 Sale |
2020-12-22 6:37 pm |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
207,910 | $157.39 | $32,722,764 | 301,587 (Direct) |
View |
2020-11-02 Sale |
2020-11-03 4:23 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
230 | $117.41 | $27,005 | 26,212 (Direct) |
View |
2020-09-25 Sale |
2020-09-28 6:13 pm |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
15,250 | $103.35 | $1,576,088 | 34,097 (Direct) |
View |
2020-09-18 Sale |
2020-09-21 4:16 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
8,262 | $109.21 | $902,294 | 142,607 (Direct) |
View |
2020-09-16 Sale |
2020-09-18 4:37 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
34,512 | $107.81 | $3,720,570 | 171,631 (Direct) |
View |
2020-09-15 Sale |
2020-09-17 4:32 pm |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
103,000 | $99 | $10,197,000 | 405,542 (Direct) |
View |
2020-09-14 Sale |
2020-09-16 5:27 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
19,565 | $97.44 | $1,906,500 | 74,218 (Direct) |
View |
2020-09-14 Sale |
2020-09-16 5:24 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
75,868 | $101.53 | $7,703,230 | 219,893 (Direct) |
View |
2020-09-09 Sale |
2020-09-11 4:19 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
28,321 | $85.41 | $2,418,881 | 70,465 (Direct) |
View |
2020-09-09 Sale |
2020-09-11 4:15 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
19,114 | $87.8 | $1,678,293 | 84,218 (Direct) |
View |
2020-09-02 Sale(A) |
2020-09-11 4:13 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
4,200 | $85.01 | $357,054 | 98,786 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
2021-03-04 Gift |
2021-03-08 4:23 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
910 | $0 | 36,658 (Direct) |
View |
2021-03-03 Exercise |
2021-03-05 5:44 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
3,475 | $69.37 | 59,055 (Direct) |
View |
2021-03-03 Exercise |
2021-03-05 5:44 pm |
N/A 2030-03-02 |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
3,475 | $0 | 59,055 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | Madden Martin J. Director |
111 | $0 | 15,224 (Indirect) |
View |
2021-03-02 Option Award |
2021-03-04 5:55 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
24,712 | $0 | 107,380 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:54 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
24,712 | $0 | 52,309 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:53 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
24,712 | $0 | 54,068 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:52 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
30,890 | $0 | 58,139 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:50 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
35,523 | $0 | 183,546 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:48 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
7,929 | $0 | 7,929 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:46 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
30,890 | $0 | 122,822 (Direct) |
View |
2021-03-02 Option Award |
2021-03-04 5:44 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
29,346 | $0 | 92,206 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,086 | $149.1 | 92,844 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:18 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,086 | $0 | 92,844 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
9,259 | $149.1 | 206,944 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:17 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
9,259 | $0 | 206,944 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,555 | $149.1 | 65,215 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:15 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,555 | $0 | 65,215 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,465 | $149.1 | 27,677 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:14 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,465 | $0 | 27,677 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,465 | $149.1 | 83,098 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:12 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,465 | $0 | 83,098 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:11 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
7,715 | $149.1 | 150,415 (Direct) |
View |
2021-02-27 Exercise |
2021-03-02 4:11 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
7,715 | $0 | 150,415 (Direct) |
View |
2021-02-22 Exercise |
2021-02-24 4:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
6,500 | $7.15 | 27,597 (Direct) |
View |
2021-02-22 Exercise |
2021-02-24 4:16 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
6,500 | $0 | 27,597 (Direct) |
View |
Ownership |
2021-02-12 7:11 pm |
N/A N/A |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
0 | $0 | 75 (Direct) |
View |
2021-01-15 Exercise |
2021-01-19 5:00 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
36,396 | $14.37 | 59,660 (Direct) |
View |
2021-01-15 Exercise |
2021-01-19 5:00 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
36,396 | $0 | 59,660 (Direct) |
View |
2021-01-06 Option Award |
2021-01-08 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
93 | $50.67 | 142,700 (Direct) |
View |
2021-01-06 Option Award |
2021-01-08 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
53 | $50.67 | 197,685 (Direct) |
View |
2020-12-21 Exercise |
2020-12-22 6:39 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
1,833 | $47.56 | 46,742 (Direct) |
View |
2020-12-21 Exercise |
2020-12-22 6:39 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
651 | $83.3 | 46,742 (Direct) |
View |
2020-12-21 Exercise |
2020-12-22 6:39 pm |
N/A 2029-05-07 |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
2,484 | $0 | 46,742 (Direct) |
View |
2020-12-18 Exercise |
2020-12-22 6:37 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
103,955 | $22 | 301,587 (Direct) |
View |
2020-12-18 Exercise |
2020-12-22 6:37 pm |
N/A 2025-10-01 |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
207,910 | $0 | 301,587 (Direct) |
View |
2020-10-29 Exercise |
2020-10-30 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
14,518 | $7.48 | 89,758 (Direct) |
View |
2020-10-29 Exercise |
2020-10-30 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
5,913 | $14.37 | 89,758 (Direct) |
View |
2020-10-29 Exercise |
2020-10-30 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
10,037 | $11.46 | 89,758 (Direct) |
View |
2020-10-29 Exercise |
2020-10-30 4:08 pm |
N/A 2024-02-25 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
30,468 | $0 | 89,758 (Direct) |
View |
2020-09-25 Exercise |
2020-09-28 6:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
6,500 | $7.15 | 34,097 (Direct) |
View |
2020-09-25 Exercise |
2020-09-28 6:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
8,750 | $11.46 | 34,097 (Direct) |
View |
2020-09-25 Exercise |
2020-09-28 6:13 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
15,250 | $0 | 34,097 (Direct) |
View |
2020-09-18 Exercise |
2020-09-21 4:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
8,262 | $7.48 | 142,607 (Direct) |
View |
2020-09-18 Exercise |
2020-09-21 4:16 pm |
N/A 2024-02-25 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
8,262 | $0 | 142,607 (Direct) |
View |
2020-09-16 Exercise |
2020-09-18 4:37 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
9,512 | $7.03 | 171,631 (Direct) |
View |
2020-09-16 Exercise |
2020-09-18 4:37 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
25,000 | $7.48 | 171,631 (Direct) |
View |
2020-09-16 Exercise |
2020-09-18 4:37 pm |
N/A 2023-02-19 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
34,512 | $0 | 171,631 (Direct) |
View |
2020-09-15 Exercise |
2020-09-17 4:32 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
103,000 | $22 | 405,542 (Direct) |
View |
2020-09-15 Exercise |
2020-09-17 4:32 pm |
N/A 2025-10-01 |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
103,000 | $0 | 405,542 (Direct) |
View |
2020-09-14 Exercise |
2020-09-16 5:27 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
19,565 | $7.48 | 74,218 (Direct) |
View |
2020-09-14 Exercise |
2020-09-16 5:27 pm |
N/A 2024-02-25 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
19,565 | $0 | 74,218 (Direct) |
View |
2020-09-14 Exercise |
2020-09-16 5:24 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
25,000 | $7.03 | 219,893 (Direct) |
View |
2020-09-15 Exercise |
2020-09-16 5:24 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
25,868 | $7.48 | 219,893 (Direct) |
View |
2020-09-14 Exercise |
2020-09-16 5:24 pm |
N/A 2023-02-19 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
75,868 | $0 | 219,893 (Direct) |
View |
2020-09-09 Exercise |
2020-09-11 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
9,114 | $7.03 | 84,218 (Direct) |
View |
2020-09-10 Exercise |
2020-09-11 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
10,000 | $7.48 | 84,218 (Direct) |
View |
2020-09-09 Exercise |
2020-09-11 4:15 pm |
N/A 2023-02-19 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
19,114 | $0 | 84,218 (Direct) |
View |
Ownership |
2020-09-10 8:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
0 | $0 | 223,330 (Direct) |
View |
Ownership |
2020-09-10 8:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
0 | $0 | 129,654 (Direct) |
View |
2020-09-01 Option Award |
2020-09-04 4:38 pm |
N/A 2030-08-31 |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
17,240 | $0 | 92,969 (Direct) |
View |